|
Ibritumomab
resources
|
|
|
|
|
|
DRUG INFO
Ibritumomab
Drug Name:
Ibritumomab
Indication: For treatment of non-Hodgkin's lymphoma
Pharmacology: Zevalin binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell non-Hodgkin’s lympohomas. The antibody leads to selective killing of B-cells.
Mechanism Of Action: Binds to the CD20 antigen which is found on mature B lymphocytes. The Fc domain recruits immune effector functions to mediate B-cell lysis. The antibody appears to induce apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity. The chelate tiuxetan, which tightly binds radioactive In-111 or Y-90, is covalently linked to the amino groups of exposed lysines and arginines contained within the antibody. The beta emission from Y-90 induces cellular damage by the formation of free radicals in the target and neighboring cells.
Drug Category: Antineoplastic Agents
Brand Names/Synonyms: Ig gamma-2A chain C region, membrane-bound form; radiolabeled murine anti-CD20; Zevalin (IDEC Pharmaceuticals)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Murine anti-CD20 antibody
Chemical Formula: C6382H9830N1672O1979S54 >Mouse Anti-CD20 Light chain 1 >Mouse Anti-CD20 Heavy chain 1 >Mouse Anti-CD20 Light chain 1
Half Life: 0.8 hours (mammalian reticulocytes, in vitro)
Drug Type: Approved Drug
# Accession No: BIOD00069
CAS Registry Number: 174722-31-7
|
|
|
|
|
|
Ibritumomab News
(When available)
ZEVALIN® Radioimmunotherapy May Play Greater Role In Combination ... Dec 27, 2005
Medical News Today (press release), ..."The ZEVALIN data released at this year's ASH meeting indicate the importance of ZEVALIN to research and the future of cancer treatment," said Arturo Molina, MD ...
Adding Radioimmunotherapy To Chemotherapy Reduces Relapse Risk In ... Dec 17, 2005
Medical News Today (press release), Zevalin (yttrium-90-ibritumomab tiuexetan) is a monoclonal antibody bound with a cancer-killing radioisotope that specifically targets lymphatic tumors. ...
Pharmacyclics' Stock Crushed After Failed Phase III Of Xcytrin Dec 19, 2005
BioWorld Online (subscription), ...released data from earlier-stage studies of Xcytrin: Phase I results showed Xcytrin injection, when given in combination with Zevalin (ibritumomab tiuxetan ...
|
|
|
